|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Plasma analyzed by mutant-specific PCR for V600E BRAF showed 86% sensitivity and 67% specificity in predicting tumor DNA sequencing results.
|
19088048 |
2008 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Univariate analysis revealed an association between the BRAF(V600E) mutation and both tumor size and extracapsular invasion.
|
19710001 |
2009 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
PXA has been demonstrated to manifest the V600E BRAF mutation in nearly 70 % of all tumors, a mutation that constitutively activates the BRAF/MEK signaling pathway.
|
23756728 |
2013 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
PLX4032 induces potent cell cycle arrest, inhibits proliferation, and initiates apoptosis exclusively in V600E-positive cells in a variety of in vitro experimental systems; follow-up xenograft studies demonstrate extreme selectivity and efficacy against melanoma tumors bearing the V600E oncoproduct.
|
20973932 |
2010 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation was found in 54.5%.It was more frequent in patients > 45 years (p=0.0001), and associated with larger tumour size (p=0.004).
|
26177218 |
2015 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Targeting CAS could represent a potential therapeutic approach particularly in combination with BRAF inhibitors such as vemurafenib in BRAF(V600E)-positive tumors.
|
26892809 |
2016 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
All tumors had a midline location (spinal cord n = 6, thalamus n = 5, brainstem n = 5, cerebellum n = 3, hypothalamus n = 1, and pineal region n = 1) and were IDH and BRAF-V600E wild type.
|
28201752 |
2017 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
While the association of the BRAF(V600E) mutation with aggressive histopathological tumor features and clinical behavior has been extensively studied in papillary thyroid carcinoma (PTC), the BRAF(K601E) mutation has not been well characterized.
|
26422023 |
2016 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Thus, testing for BRAF-V600E allows for a genetics-based differential diagnosis between HCL and HCL-like tumors, even noninvasively in routine blood samples.
|
28297625 |
2017 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
The tumor with T1799A BRAF mutation and tumor sizes of 2 cm or more were clinicopathologic parameters associated with lower STAT1 activity.
|
22514085 |
2012 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Five of the 7 (71%) responders were BRAF(WT), of which 1 carried c-KIT(L576P) and another N-RAS(Q61R) mutation, while only 2 (29%) of the responding tumors were BRAF(V600E/K).
|
22351689 |
2012 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
RNA-seq data was downloaded from the Gene Expression Omnibus (GEO) database for pre- and post-treatment tumor samples from three melanoma patients with EGFR-activating BRAF V600E mutations, and from The Cancer Genome Atlas (TCGA) melanoma database for tumor and non-tumor samples from patients with the BRAF V600E mutation and unknown EGFR activation status.
|
29387237 |
2018 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Indeed, PLX4720 not only directly limited BRAF(V600E)-induced tumor cell proliferation, but also affected NK cell functions.
|
25351955 |
2014 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
These data suggest that p16 deletion adversely impacts the outcomes of BRAF-driven gliomas, that high proliferation index may be a better marker of progression risk than BRAF, that BRAF rearrangement and BRAF V600E might not necessarily produce comparable outcomes, and that none of these markers is stronger than tumor location in determining prognosis in pediatric low-grade gliomas.
|
22492957 |
2012 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Mutational activation of BRAF is the most prevalent genetic alteration in human melanoma, with ≥50% of tumours expressing the BRAF(V600E) oncoprotein.
|
23302800 |
2013 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Six had V600E-positive tumours (n=4 had PD; n=1 had SD; n=1 unevaluable for response), and 11 had tumours containing wild-type BRAF (n=9 PD; n=1 SD; n=1 unevaluable for response).
|
16880785 |
2006 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Thirteen PTCs had the B-Raf proto-oncogene, serine/threonine kinase (BRAF) valine-to-glutamic acid mutation at position 600 (BRAF(V) (600E)) (13 of 27 tumors; 48%), 11 measured <2 cm, and 6 had lymphatic invasion (46%), with vascular invasion in 3.
|
26784937 |
2016 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
The BRAF-V600E mutation is associated with tumor aggressiveness and poor prognosis in melanoma patients.
|
27363650 |
2016 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Interestingly, MTDH expression was associated with extrathyroidal extension (p < 0.05) and not associated with age, gender, overall tumor stage, or BRAF (V600E) mutation status.
|
27146414 |
2016 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Molecular analysis demonstrated presence of BRAF V600E mutation in the tumor.
|
29389234 |
2018 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation testing of colorectal tumors demonstrating aberrant MLH1 protein expression by IHC was the most common secondary tumor test, with 53% of laboratories performing the test; 15% of laboratories also applied the BRAF V600E test to endometrial tumors with aberrant MLH1 expression despite no evidence for its utility.
|
30294856 |
2018 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Among unselected mCRC patients, BRAF V600E mutation was detected in 48 of 546 primary tumors (8.8%).
|
20857202 |
2011 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
We found that PLX4720 treatment downregulated tumor Ccl2 gene expression and decreased tumor CCL2 expression in both Braf(V600E) mouse melanoma transplants and in de novo melanomas in a manner that was coincident with reduced tumor growth.
|
23454771 |
2013 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Colorectal cancer (CRC) is one of the most common cancers worldwide, with 8-10% of these tumours presenting a BRAF (V600E) mutation.
|
30087414 |
2018 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
|
31672130 |
2019 |